Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | TPMT | P51580 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5575505 | 0.86 | SLC22A6 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10757240 | 0.86 | TUBB4A (0.50) | ALDH1A1GAATDP1CYP1A2CYP3A4 | |
| SCHEMBL153056 | 0.85 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28103050 | 0.82 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18379291 | 0.82 | ELANE (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27655956 | 0.81 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21101774 | 0.81 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2729632 | 0.79 | TSHR (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28830235 | 0.79 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9423944 | 0.79 | CA12 (0.57) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912467-B1 | ASYMMETRIC HYDROGENATION METHOD OF A KETONIC COMPOUND AND DERIVATIVE | RHODIA CHIMIE SA (FR) | 2002-04-24 | — | — | EP | claimed |
| US-20040102649-A1 | Water soluble chiral diphoshpines | RHODIA CHIMIE (FR) | 2004-05-27 | — | — | US | disclosed |
| US-20030225297-A1 | Process for preparing chiral diphosphines | RHODIA CHIMIE | 2003-12-04 | — | — | US | disclosed |
| US-6646106-B1 | Polymerizing chiral diphosphine having a C2 axis of symmetry, with one or several polymerizable monomers, said chiral diphosphine consisting of a chiral body bearing two identical functional groups | RHODIA CHIMIE (FR) | 2003-11-11 | — | — | US | disclosed |
| US-6610875-B1 | Forming bidentate ligands ofr assymetric catalysts; bromina-ting diaryldiol; esterifying with sulfonic acid; substituting cyano for bromine groups; coupling with a dicyclophosphine | RHODIA CHIMIE (FR) | 2003-08-26 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-6166257-A | METAL COMPLEX OF AN OPTICALLY ACTIVE BIS(1-PHOSPHA-2,3-DIPHENYL-4,5-DIMETHYLNORBORNADIENE) | RHODIA CHIMIE (FR) | 2000-12-26 | — | — | US | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0206460-B1 | L-PHENYLALANINE DEHYDROGENASE AND USE THEREOF | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1993-08-11 | — | — | EP | disclosed |
| EP-0513872-A1 | L-phenylalanine dehydrogenase and use thereof | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-11-19 | — | — | EP | disclosed |
| EP-0295890-B1 | PROCESS OF PREPARING OPTICALLY ACTIVE ALCOHOL | Takasago International Corporation (JP) | 1992-09-16 | — | — | EP | disclosed |
| US-5066815-A | Asymmetric hydrogenation of ketone, ruthenium-phosphine catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1991-11-19 | — | — | US | disclosed |
| US-4849345-A | L-phenylalanine dehydrogenase and use thereof | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1989-07-18 | — | — | US | disclosed |
| EP-0206460-A2 | L-phenylalanine dehydrogenase and use thereof | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102649-A1 | Water soluble chiral diphoshpines | ADRA1B, ADRB1, ADRA1A | CA12 3413/4885CA1 2200/4885CA2 1324/4885 |
| US-20030225297-A1 | Process for preparing chiral diphosphines | CYP1A1, NR5A1, AR | CA12 4500/4885CA1 3776/4885CA2 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.